Vascular surgery is associated with a high risk of perioperative morbidity and mortality that is partly attributable to infl ammatory stress induced by the surgical procedure. Preoperative initiation of a long-acting statin is a strategy intended to reduce the infl ammatory stress response and the excess risk associated with vascular surgery. The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III demonstrated signifi cant reductions in perioperative myocardial ischemia and the composite end point of myocardial infarction or cardiovascular death with extended-release fl uvastatin (relative to placebo) initiated 30 days prior to vascular surgery. These benefi ts were achieved with no increase in liver dysfunction, evidence of myopathy, or other side effects. Observational data suggest that perioperative statin use is associated with improved recovery from acute kidney injury after high-risk vascular surgery and with improved long-term survival in patients undergoing such surgery.
  KEY POINTS
The infl ammatory and oxidative stress induced by vascular surgery can be blunted by statin therapy.
Statin therapy started preoperatively can reduce the incidence of myocardial ischemia and the level of infl ammatory markers in patients undergoing high-risk vascular surgery.
The purpose of perioperative statin use should be reduction of the infl ammatory stress response to surgery, with the long-term goal being achievement of target lipid levels.
A long-acting statin is preferred preoperatively to best extend the anti-infl ammatory effects into the postoperative period. Statin therapy should be continued postoperatively, if possible, to avoid deleterious acute withdrawal effects. C urrent uncertainty over the best approach for preventing fatal perioperative myocardial infarction (MI) lies in our inability, despite sophisticated testing methods, to detect unstable coronary plaque prior to surgery. Unstable plaque can be present in patients with coronary lumina that appear normal on coronary angiography. Therefore, reliance on medical therapy to blunt infl ammation is currently the best practice for minimizing the risk that unstable plaque poses.
Perioperative use of statins is a cornerstone of such therapy. This article briefl y reviews the rationale for perioperative statin use in the setting of noncardiac surgery, presents the latest evidence on the clinical effects of perioperative statin use, and considers the potential role for statins in promoting recovery from acute kidney injury after vascular surgery.
   FATAL MI: ORIGINS AND APPROACHES
TO RISK REDUCTION Fatal perioperative MI has two potential origins. 1, 2 One is a culprit coronary plaque that fi ssures and ruptures, causing a cascade of thrombogenic events (hemorrhage and thrombosis) inside the vessel wall, culminating in an MI. Less often, fatal perioperative MI results from long-lasting myocardial ischemia (a demand/supply mismatch of oxygen), typically as a consequence of a fi xed coronary stenosis.
In nearly half of patients with fatal MI, coronary infl ammation is a key contributor. In the perioperative setting, surgical stress induces the release of infl ammatory cytokines that disrupt smooth muscle cells in the endothelium and contribute to disruption of a nonobstructing coronary plaque, predisposing to acute thrombus formation.
Risk reduction depends on pathophysiology
Strategies for minimizing the risk of perioperative MI depend on the pathophysiology involved. In the case of oxygen demand/supply mismatch as a result of fl owlimiting stenosis, a beta-blocker and coronary revascularization, if possible, may be useful.
In the more common case of unstable plaque, a multifactorial strategy appears optimal, involving the following:
• Statin therapy to reduce coronary infl ammation
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• Aspirin to blunt the prothrombotic milieu postoperatively • Chronic low-dose beta-blockade to decrease myocardial oxygen demand or inhibit plaque rupture.
A particular role for statins Ridker et Among surgical patients, those most at risk for poor cardiovascular outcomes are those who undergo vascular surgery. In Europe, the cardiovascular death rate in such patients is approximately 2%. 4 Retrospective cohort data and data from randomized clinical trials have demonstrated reductions in perioperative cardiac complications with statin use in patients undergoing various types of noncardiac vascular surgery. [5] [6] [7] [8] [9] In light of these data, my colleagues and I recently undertook a prospective study to examine the effect of perioperative statin use on cardiovascular complications in patients undergoing vascular surgery. 10 Key details and fi ndings are surveyed in the following section.
   DECREASE III: PROSPECTIVE EVIDENCE FOR
ISCHEMIC BENEFIT FROM PERIOPERATIVE STATINS The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III (DECREASE III) was conducted at a single center (Erasmus Medical Center, Rotterdam, the Netherlands) in a randomized, doubleblind, placebo-controlled manner.
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Patients and study design The study population included 497 statin-naïve patients who were scheduled for one of four noncardiac vascular surgical procedures (repair or revascularization for abdominal aortic aneurysm, abdominal aortic stenosis, lower limb arterial stenosis, or carotid artery stenosis). Patients with unstable coronary artery disease or left main disease were excluded.
Patients were randomized to placebo or extendedrelease fl uvastatin (80 mg/day) starting on the day of randomization, which was a median of 37 days before surgery. Treatment was continued until 30 days after surgery.
Extended-release fl uvastatin was chosen because its long half-life permits a bridge to the early postoperative period, during which oral medications are not permitted in patients undergoing high-risk vascular surgery.
The primary end point was the occurrence of myocardial ischemia as assessed by three methods:
• Holter monitoring during the fi rst 72 postoperative hours • Measurement of troponin T on days 1, 3, 7, and 30
• Additional electrocardiographic recordings on days 7 and 30. The secondary end point was a composite of cardiovascular death and nonfatal MI during the fi rst 30 postoperative days.
Baseline characteristics were similar between the two randomized groups, with a median age approaching 66 years. About three-fourths of the patients were male, one-fourth had a history of MI, one-fourth had angina pectoris, one-fi fth had diabetes mellitus, and nearly 30% had a history of cerebrovascular accident or transient ischemic attack.
All patients were being treated with a beta-blocker, about 60% with antiplatelet therapy, more than onefourth with anticoagulant therapy, nearly half with either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and more than one-fourth with diuretics. There were no signifi cant differences between the groups in the proportion of patients on each of these therapies.
Results: Reductions in infl ammatory markers
Baseline levels of hsCRP and interleukin-6 (IL-6) were comparable between the groups. In patients randomized to placebo, the hsCRP level increased by 3%, from a median of 5.80 mg/L at randomization to 6.00 mg/L immediately prior to surgery. In contrast, the hsCRP level in patients randomized to extended-release fl uvastatin decreased by 21%, from a median of 5.93 mg/L to 4.66 mg/L. The between-group difference in the change in hsCRP level was statistically signifi cant (P < .001). There was also a signifi cantly greater reduction from baseline in median level of IL-6 among fl uvastatin recipients compared with placebo recipients (-33% vs -4%; P < .001).
The specifi city of hsCRP for cardiac infl ammation is not yet known, but measures of hsCRP and IL-6 can provide a fi ngerprint of infl ammatory activity prior to surgery. Other infl ammatory and noninfl ammatory markers are being investigated to better identify (prior to surgery) those high-risk patients most likely to benefi t from perioperative statin use.
Results: Favorable effect on clinical end points
The incidence of the primary end point-myocardial ischemia 30 days after surgery-was signifi cantly lower in the patients randomized to extended-release fl uvastatin compared with placebo (10.9% vs 18.9%; P = .016), as was the incidence of the secondary end point of cardiovascular death or nonfatal MI (4.8% vs 10.1%; P = .039).
The number needed to treat (NNT) to prevent one occurrence of myocardial ischemia was 13; the NNT to prevent one nonfatal MI was 36; and the NNT to prevent one cardiovascular death was 42 (Table 1) .
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Safety: No effects on liver function or evidence of increased myopathy
No signifi cant differences were seen between the study arms in safety end points, including discontinuation of study drug, the incidence of creatine kinase (CK) elevations above 10 times the upper limit of normal, median CK levels, the incidence of alanine aminotransferase (ALT) elevations above three times the upper limit of normal, and median ALT levels ( Table 2) . Receipt of general anesthesia prevented monitoring for symptoms of myopathy and rhabdomyolysis.
We concluded that initiation of therapy with a long-acting statin should be considered in statin-naïve patients undergoing vascular surgery.
   PERIOPERATIVE STATIN USE: PRACTICAL CONSIDERATIONS
Infl ammation, not cholesterol, should be the target The optimal statin choice and the target level of LDL cholesterol immediately prior to surgery remain controversial. It may be that the more potent statins induce more side effects during surgery, but any such claim is speculative since no comparative studies exist. Regardless, the purpose of perioperative statin use should be reduction of the infl ammatory stress response to surgery, with the long-term goal being achievement of recommended target lipid levels.
In particular, patients with peripheral arterial disease should have a statin initiated prior to high-risk vascular surgery (if they are not already receiving one), to increase the odds of recovering renal function after surgery (see section below) and to improve long-term outcomes.
Who are the best candidates?
Patients with multiple cardiac risk factors represent an especially high-risk group that benefi ts the most from statin therapy prior to vascular surgery, as they are likely to have more extensive disease and more extensive infl ammation in the coronary artery tree.
Given the low incidence of side effects associated with statins, initiating a statin in patients with multiple cardiac risk factors who are undergoing intermediaterisk surgery may seem appropriate, but no data from large randomized trials are available to support this practice. Caution is in order when extrapolating data from studies conducted in the high-risk vascular surgery context to other surgical settings, since statins may pose hidden side effects such as liver dysfunction and myopathy, which may be missed in patients under anesthesia.
My personal practice is to initiate a statin prior to high-risk surgery or in patients with multiple cardiac risk factors if the risk-factor profi le presents a clear indication for long-term statin use. If no risk factors are present, I am more reluctant to initiate a statin because of a lack of supportive data.
Beware the rebound effect with statin withdrawal
Statin withdrawal for several days following surgery is a common practice, since statins are given orally and their pleiotropic effects are underappreciated.
A withdrawal effect leading to abrogation of clinical benefi t has been observed with perioperative use of short-acting statins, whose anti-infl ammatory properties do not effectively extend to the postoperative period. Acute withdrawal has been associated with an increase in markers of infl ammation and oxidative stress, and an increase in cardiac events has been observed with acute withdrawal of statins during periods of instability when compared with continuation of statin therapy. 
   ANOTHER POTENTIAL BENEFIT: ENHANCED RECOVERY OF KIDNEY FUNCTION Postoperative renal dysfunction is an ominous sign
Renal ischemic reperfusion injury is inevitable after vascular surgery that requires aortic cross-clamping. This is signifi cant, as renal dysfunction after surgery is an ominous long-term sign that indicates abundant atherosclerosis. Complete recovery after acute kidney injury portends an improved long-term outcome, whereas patients with persistent renal dysfunction after vascular surgery have poor long-term outcomes.
A benefi t from statins?
Statins may offer an effective means of preventing or shortening the course of acute kidney injury after surgery. Statins have been reported to lengthen survival of chronic kidney disease patients with sepsis or infectious complications and to improve the course of acute kidney injury in aging rats. [13] [14] [15] These fi ndings prompted my colleagues and I to conduct a retrospective study to evaluate whether statins may ameliorate reperfusion injury in the kidney after aortic cross-clamping. 16 
Promising fi ndings from an observational review
We reviewed the records of all patients who had undergone vascular surgery at Erasmus Medical Center from January 1995 to June 2006 to examine the relation between preoperative statin use and renal function after suprarenal aortic cross-clamping. 16 Of the 1,944 patients who met inclusion criteria, 515 (26.5%) were statin users. Postoperative kidney injury was defi ned as more than a 10% reduction in creatinine clearance on postoperative day 1 or 2 compared with baseline. Recovery of kidney function was defi ned as a creatinine clearance of greater than 90% of the baseline value by postoperative day 3.
The clinical characteristics of the populations with and without kidney injury after aortic cross-clamping were similar, including baseline creatinine clearance and serum creatinine.
Acute kidney injury within 2 days of surgery occurred in 664 patients (34%), of which 313 (47%) had complete recovery of kidney function at postoperative day 3. Although the incidence of postoperative kidney injury was similar among statin users and nonusers, statin use was associated with an increased chance of complete recovery of kidney function at day 3 (odds ratio = 2.0; 95% CI, 1.0-3.8).
All-cause mortality was assessed during a mean follow-up of 6.24 years. Statin use was associated with improved long-term survival, regardless of any change in kidney function (hazard ratio for death = 0.60; 95% CI, 0.48-0.75). Among the four broad patient groups, survival was highest among statin users with no postoperative kidney injury, followed by statin users who had kidney injury, then by nonusers of statins with no kidney injury, and fi nally by nonusers of statins who had kidney injury.
We concluded that perioperative statin use was associated with clinically signifi cant recovery from acute kidney injury after high-risk vascular surgery and, more importantly, with improved long-term survival regardless of the presence of kidney injury. These promising fi ndings require confi rmation in prospective trials.
  SUMMARY
Vascular surgery carries a high risk of perioperative mortality. Perioperative use of extended-release fl uvastatin is associated with a reduced incidence of myocardial ischemia and the composite of MI and cardiovascular death at 30 days following surgery. These benefi cial clinical outcomes are achieved without an increase in the incidence of side effects, including liver dysfunction and myopathy. Preoperative initiation of a long-acting statin is a reasonable strategy for reducing the risks associated with vascular surgery, and offers a bridge to postoperative statin continuation to blunt the infl ammatory stress of surgery. Ischemic reperfusion injury is a major cause of renal dysfunction following vascular surgery. Statin therapy appears to help restore kidney function after aortic cross-clamping in patients undergoing high-risk vascular surgery.
  DISCUSSION
Question from the audience: The majority of patients randomized in DECREASE III had relatively normal cholesterol levels. Do you believe those patients are biologically different from patients with physiologic vascular disease and elevated cholesterol levels? Dr. Poldermans: We enrolled patients with various baseline cholesterol levels, and we found that these levels were not related to postoperative outcome. It would be a good idea to examine infl ammation status just prior to surgery in patients with lower cholesterol levels to see if they have different outcomes from those with high cholesterol.
Question from the audience: If a patient is already on a short-acting statin and we know that he or she won't be able to take a statin postoperatively, should we change to a long-acting statin just prior to surgery? Dr. Poldermans: To be honest, this is a fi nancial issue. If you have the opportunity, the best course would be to prescribe a statin with a prolonged half-life or an extended-release formulation. Of course, it's not always possible to prescribe one particular statin. You have to negotiate what is feasible and hope to initiate the statin as early as possible to reduce risk.
Question from the audience: In studies conducted outside the perioperative setting, such as PROVE IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) and a substudy of REVERSAL (Reversing Atherosclerosis with Aggressive Lipid Lowering), it took about 30 days after statin initiation for hsCRP levels to minimize, and at least that long for halting of plaque progression to be detected by intravascular ultrasonography. Given that, does it make sense to delay nonurgent surgery in a patient in whom you're worried about a postoperative MI? Dr. Poldermans: Rat studies show improved blood fl ow and reduced thrombosis within hours of statin initiation. In the perioperative setting, therefore, initiating a statin within 30 days may be appropriate, but nobody knows the exact timing for optimal effect. Since there are no data to answer this question, I would not postpone surgery for this reason.
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